Benefits of Pharmacologic, Supplement, and Behavioral Treatment in Children and Adolescents with Familial Hypercholesterolemia and Multifactorial Dyslipidemia
This interactive visualization displays the treatment effects from pharmacologic, supplement, and behavioral interventions to treat children and adolescents with heterozygous familial hypercholesterolemia or multifactorial dyslipidemia. The data are organized by intervention category (pharmacologic, supplement, behavioral intervention). Between group differences for each individual study are displayed; a negative value indicates an intervention benefit. Select options from the dropdown menus to choose which data to display. Color and shape indicate condition (FH or MFD). Hover over data points for additional information. This visualization is best viewed on a desktop.
Source: Guirguis-Blake JM, Evans CV, Coppola EL, Redmond N, Perdue LA. Screening for Lipid Disorders in Children and Adolescents: An Evidence Update for the U.S. Preventive Services Task Force. Evidence Synthesis No. 229. AHRQ Publication No. 22-05301-EF-1; Rockville, MD: Agency for Healthcare Research and Quality; 2023.
Note: This systematic review specifically addressed treatment for heterozygous FH. Where FH is indicated in this dashboard, it is referring to heterozygous FH.
Abbreviations: DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; FH = familial hypercholesterolemia; PCSK9 = proprotein convertase subtilisin/kexin type 9; MFD = multifactorial dyslipidemia; IG = intervention group; F/U = follow-up; CI = confidence interval; mg/dL = milligrams per deciliter; TC = total cholesterol; TG = triglycerides.